Evidence map›Paper›PMID 41459145›Full record

Observational studyFrontiers in cellular and infection microbiology2025

Efficacy of ceftazidime/avibactam versus other antimicrobial agents for treating multidrug- resistant

Qian Qian, JiaChen Wei, Fei Xu, XinYu Qin, Pei Ji, ChuWei Jing, ShuMei Miao, WenKui Sun

Abstract readObservational StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qian QianDepartment of Clinical Medicine, Jiangsu Health Vocational College, Nanjing, Jiangsu, China.
JiaChen WeiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Fei XuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
XinYu QinDepartment of Gastroenterology, The Second Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Pei JiDepartment of Information, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
ChuWei JingDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
ShuMei MiaoDepartment of Information, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
WenKui SunDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Multidrug-resistant Methods: This single-center retrospective observational study included MDRPA-infected patients treated with CAZ/AVI or other antimicrobial agents between January 2019 and April 2021. Propensity score-matched and binary logistic regression analysis was used to compare the clinical and microbiological efficacy between CAZ/AVI and other antimicrobial agents. Results: Totally 363 patients with MDRPA infection were enrolled, including 49 patients treated with CAZ/AVI and 314 patients treated with other antimicrobial agents. The CAZ/AVI group exhibited a reduced failure rate of clinical treatment (P = 0.012, OR = 0.381, 95% CI 0.180 - 0.807). Subgroup analysis showed single lung infection was a significant risk factor for clinical treatment failure in patients treated with other antimicrobial agents (P = 0.023, OR = 2.568, 95% CI 1.138 - 5.796). No significant discrepancy was observed in microbiological efficacy between the two groups (P = 0.159, OR = 0.587, 95% CI 0.280 - 1.232), or in clinical and microbiological efficacy between CAZ/AVI monotherapy and combination therapy. Conclusions: CAZ/AVI demonstrates superior clinical efficacy against MDRPA in comparison to other antimicrobial agents. However, the administration of CAZ/AVI as part of combination therapy does not provide any clear benefits over monotherapy. Patients with single pulmonary infection caused by MDRPA show better clinical efficacy with CAZ/AVI. Further larger studies are needed to substantiate our findings.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsAzabicyclo CompoundsCeftazidimeDrug Resistance, Multiple, BacterialPseudomonas aeruginosaPseudomonas InfectionsAdultAgedbeta-Lactamase InhibitorsDrug CombinationsFemaleHumansMaleMiddle AgedPropensity ScoreAnti-Bacterial AgentsAnti-Infective Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-Lactamase InhibitorsCeftazidimeDrug Combinationsceftazidime avibactamclinical efficacymicrobiological efficacymultidrug-resistant Pseudomonas aeruginosapropensity score-matchedpulmonary infection

Identifiers

PMID41459145
PMCPMC12738922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.